In addition to breast cancer, PD-991 is currently being evaluated through Pfizer-sponsored and investigator-initiated research in other cancers, including liposarcoma, non-small cell lung cancer, liver cancer, ovarian cancer, glioblastoma, refractory solid tumors, multiple myeloma, and mantle cell lymphoma.About Pfizer Oncology Pfizer Oncology is committed to the discovery, investigation and development of innovative treatment options to improve the outlook for cancer patients worldwide. Our strong pipeline of biologics and small molecules, one of the most robust in the industry, is studied with precise focus on identifying and translating the best scientific breakthroughs into clinical application for patients across a wide range of cancers. By working collaboratively with academic institutions, individual researchers, cooperative research groups, governments, and licensing partners, Pfizer Oncology strives to cure or control cancer with breakthrough medicines, to deliver the right drug for each patient at the right time. For more information, please visit www.Pfizer.com. DISCLOSURE NOTICE: The information contained in this release is as of December 5, 2012. Pfizer assumes no obligation to update forward-looking statements contained in this release as the result of new information or future events or developments. This release contains forward-looking information that involves substantial risks and uncertainties about PD-991, an investigational therapy, including a potential indication for advanced breast cancer and various other potential indications and the anticipated commencement of a Phase 3 study in advanced breast cancer in 2013. Such risks and uncertainties include, among other things, the uncertainties inherent in research and development, including the ability to meet anticipated clinical trial commencement and completion dates, regulatory submission and approval dates, and launch dates; decisions by regulatory authorities regarding whether and when to approve any drug applications that may be filed for any such potential indications as well as their decisions regarding labeling and other matters that could affect the availability or commercial potential of such potential indications; and competitive developments. A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2011 and in its reports on Form 10-Q and Form 8-K. 1 World Health Organization. Breast Cancer Burden. Available at: http://www.who.int/cancer/detection/breastcancer/en/index1.html. Accessed November 15, 2012. 2 World Health Organization. Cancer. Available at: http://www.who.int/mediacentre/factsheets/fs297/en/. Accessed November 15, 2012. 3 Decision Resources. Event Driven Pharmacor Report. 2012. 4 Miles, David. When HER2 is not the target: advances in the treatment of HER2-negative metastatic breast cancer. Breast Cancer Research 2009 August; 11(4).